Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Study Summary

A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions / Drugs

Inebilizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment15 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.158208+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.